请输入您要查询的百科知识：

　

词条 James L. Gulley
释义

  1. Life and career

  2. National Library of Medicine, Publications

  3. Ipilimumab

  4. References

  5. External links

{{Multiple issues|{{autobiography|date=January 2011}}{{BLP primary sources|date=July 2010}}
}}{{Infobox medical person
| name = James L. Gulley
| image =
| caption =
| birth_date =
| birth_place =
| death_date =
| death_place =
| profession = Medical oncologist
| specialism = genitourinary oncology, immunotherapy
| research_field = cancer research
| known_for =
| years_active =
| education = Loma Linda University, Emory University, National Cancer Institute
| work_institutions = National Cancer Institute
| spouse =
| prizes =
| relations =
}}

James L. Gulley is the Director, Clinical Trials Group within the Laboratory of Tumor Immunology and Biology,[1] Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH).

Life and career

Gulley graduated from Loma Linda University in California with a Ph.D. in microbiology in 1994 and an M.D. in 1995. As part of this eight-year M.D./Ph.D. Medical Scientist Training Program, designed and funded by the NIH to produce translational researchers, he completed a dissertation on tumor immunology. He completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship[2] at the NCI. Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as Principal Investigator or an Associate Investigator on approximately 40 trials. Gulley is running several currently enrolling studies for cancer patients[3]

Gulley is especially interested in immunotherapy for prostate cancer. As Director of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology, he takes promising laboratory findings and uses them to design and conduct clinical trials. These studies involve the use of cancer vaccine and other immunostimulatory molecules to modulate the immune response in cancer patients, and the addition of other strategies to enhance vaccine-mediated killing. He is also a Principal Investigator within the Medical Oncology Branch at the National Cancer Institute. He serves on many boards and committees including the NCI Prostate Cancer Task Force. He has authored over 125 scientific papers or book chapters,[4] edited 3 books including the Bethesda Handbook of Clinical Oncology[5] and has made numerous presentations at national and international meetings.

Gulley serves as the Principal Investigator of PROSPECT[6] - a global phase III clinical trial of a cancer vaccine, PSA-TRICOM, also known as Prostvac that was initiated in November 2011.[7] This vaccine was developed by the National Cancer Institute and licensed to Bavarian Nordic who is sponsoring this phase III study. Gulley has been involved in many of the earlier clinical trials of PROSTVAC.[8][9][10][11][12][13][14]

National Library of Medicine, Publications

Starting in 2003, Gulley, JL has authored or co-authored 82 pubmed.gov recorded papers (as of 2011), on various aspects of prostate cancer treatments including 37 co-authored with Schlom.[15] The paper quoting Dr Schlom re:"Rethinking Cancer Vaccine Trials: Would New Measures of Success Make a Difference?"

at Sipuleucel-T (reference #14) was co-authored by Gulley, JL.[16]

Ipilimumab

At the 2010 ASCO meeting Gulley's group reported on the use of Ipilimumab with a vector-based vaccine for advanced prostate cancer. This phase I trial using PSA-TRICOM with Ipilimumab (Ipi) showed promise for Overall Survival (OS).[17] Ipi is used in melanoma vaccine clinical trials.[18] It was approved by the FDA in March 2011. The understanding of cytotoxic T-lymphocyte antigen-4 (CTLA-4) which lead to the development of Ipi shows again that Gulley and his team have a considerable grasp of what can work in the human cancer vaccine arena.[19][20]

References

1. ^{{cite web|url=http://ccr.cancer.gov/labs/lab.asp?labid=39 |title=Center for Cancer Research - Organization Pages |publisher=Ccr.cancer.gov |date=2010-04-28 |accessdate=2010-07-14 |deadurl=yes |archiveurl=https://web.archive.org/web/20100527092913/http://ccr.cancer.gov/labs/lab.asp?labid=39 |archivedate=2010-05-27 |df= }}
2. ^{{cite web|url=http://medicaloncology.cancer.gov/index.php/fellowship/index.htm |title=Medical Oncology Web - FELLOWSHIP |publisher=Medicaloncology.cancer.gov |date= |accessdate=2010-07-14}}
3. ^{{cite web|url=http://bethesdatrials.cancer.gov/investigator-profiles/gulley/default.asp |title=Clinical Trials at NIH: Health Care Professionals: Investigator Profiles: James L. Gulley, M.D |publisher=Bethesdatrials.cancer.gov |date= |accessdate=2010-07-14 |deadurl=yes |archiveurl=https://web.archive.org/web/20100527113440/http://bethesdatrials.cancer.gov/investigator-profiles/gulley/default.asp |archivedate=2010-05-27 |df= }}
4. ^{{cite web|url=http://ccr.cancer.gov/staff/cv.asp?profileid=5686 |title=Center for Cancer Research - Staff Pages |publisher=Ccr.cancer.gov |date= |accessdate=2010-07-14 |deadurl=yes |archiveurl=https://web.archive.org/web/20100527145339/http://ccr.cancer.gov/staff/cv.asp?profileid=5686 |archivedate=2010-05-27 |df= }}
5. ^{{cite book |first1=Jame |last1=Abraham |first2=Carmen J. |last2=Allegra |first3=James L. |last3=Gulley |title=Bethesda handbook of clinical oncology |publisher=Lippincott Williams & Wilkins |location=Hagerstwon, MD |year=2005 |pages= |isbn=978-0-7817-5116-2}}{{Page needed|date=January 2011}}
6. ^{{cite web|url=http://clinicaltrials.gov/ct2/show/NCT01322490 |title=PROSPECT Phase 3 Trial |publisher=Clinicaltrials.gov|date= |accessdate=2013-04-12}}
7. ^{{cite web|url=http://www.bavarian-nordic.com/investor/announcements/2011-31.aspx |title=Prostvac |publisher=Bavarian Nordic |date= |accessdate=2013-04-12 |deadurl=yes |archiveurl=https://web.archive.org/web/20120126131318/http://www.bavarian-nordic.com/investor/announcements/2011-31.aspx |archivedate=2012-01-26 |df= }}
8. ^{{cite journal |doi=10.1200/JCO.2009.25.0597 |title=Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer |year=2010 |last1=Kantoff |first1=P. W. |last2=Schuetz |first2=T. J. |last3=Blumenstein |first3=B. A. |last4=Glode |first4=L. M. |last5=Bilhartz |first5=D. L. |last6=Wyand |first6=M. |last7=Manson |first7=K. |last8=Panicali |first8=D. L. |last9=Laus |first9=R. |last10=Schlom |first10=J. |last11=Dahut |first11=W. L. |last12=Arlen |first12=P. M. |last13=Gulley |first13=J. L. |last14=Godfrey |first14=W. R. |journal=Journal of Clinical Oncology |volume=28 |issue=7 |pages=1099–105 |pmid=20100959 |pmc=2834462|display-authors=8 }}
9. ^{{cite journal |doi=10.1007/s00262-009-0782-8 |title=Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer |year=2009 |last1=Gulley |first1=James L. |last2=Arlen |first2=Philip M. |last3=Madan |first3=Ravi A. |last4=Tsang |first4=Kwong-Yok |last5=Pazdur |first5=Mary P. |last6=Skarupa |first6=Lisa |last7=Jones |first7=Jacquin L. |last8=Poole |first8=Diane J. |last9=Higgins |first9=Jack P. |last10=Hodge |first10=James W. |last11=Cereda |first11=Vittore |last12=Vergati |first12=Matteo |last13=Steinberg |first13=Seth M. |last14=Halabi |first14=Susan |last15=Jones |first15=Elizabeth |last16=Chen |first16=Clara |last17=Parnes |first17=Howard |last18=Wright |first18=John J. |last19=Dahut |first19=William L. |last20=Schlom |first20=Jeffrey |journal=Cancer Immunology, Immunotherapy |volume=59 |issue=5 |pages=663|display-authors=8 |pmc=2832083 }}
10. ^{{cite journal |doi=10.1158/1078-0432.CCR-07-5162 |title=Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 is Used as an Adjuvant |year=2008 |last1=Lechleider |first1=R. J. |last2=Arlen |first2=P. M. |last3=Tsang |first3=K.-Y. |last4=Steinberg |first4=S. M. |last5=Yokokawa |first5=J. |last6=Cereda |first6=V. |last7=Camphausen |first7=K. |last8=Schlom |first8=J. |last9=Dahut |first9=W. L. |last10=Gulley |first10=J. L. |journal=Clinical Cancer Research |volume=14 |issue=16 |pages=5284–91 |pmid=18698048 |pmc=2639763|display-authors=8 }}
11. ^{{cite journal |doi=10.1158/1078-0432.CCR-05-2059 |title=A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer |year=2006 |last1=Arlen |first1=P. M. |journal=Clinical Cancer Research |volume=12 |issue=4 |pages=1260–9 |pmid=16489082 |last2=Gulley |first2=JL |last3=Parker |first3=C |last4=Skarupa |first4=L |last5=Pazdur |first5=M |last6=Panicali |first6=D |last7=Beetham |first7=P |last8=Tsang |first8=KY |last9=Grosenbach |first9=DW |last10=Feldman |first10=J |last11=Steinberg |first11=S. M. |last12=Jones |first12=E |last13=Chen |first13=C |last14=Marte |first14=J |last15=Schlom |first15=J |last16=Dahut |first16=W |pmc=1526707|display-authors=8 }}
12. ^{{cite journal |doi=10.1097/01.ju.0000165159.33772.5b |title=Antiandrogen, Vaccine and Combination Therapy in Patients with Nonmetastatic Hormone Refractory Prostate Cancer |year=2005 |last1=Arlen |first1=Philip M. |last2=Gulley |first2=James L. |last3=Todd |first3=Nushin |last4=Lieberman |first4=Ronald |last5=Steinberg |first5=Seth M. |last6=Morin |first6=Steve |last7=Bastian |first7=Anne |last8=Marte |first8=Jennifer |last9=Tsang |first9=Kwong-YOK |last10=Beetham |first10=Patricia |last11=Grosenbach |first11=Douglas W. |last12=Schlom |first12=Jeffrey |last13=Dahut |first13=William |journal=The Journal of Urology |volume=174 |issue=2 |pages=539–46 |pmid=16006888|display-authors=8 }}
13. ^{{cite journal |doi=10.1158/1078-0432.CCR-04-2062 |title=Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer |year=2005 |last1=Gulley |first1=J. L. |journal=Clinical Cancer Research |volume=11 |issue=9 |pages=3353–62 |pmid=15867235 |last2=Arlen |first2=PM |last3=Bastian |first3=A |last4=Morin |first4=S |last5=Marte |first5=J |last6=Beetham |first6=P |last7=Tsang |first7=KY |last8=Yokokawa |first8=J |last9=Hodge |first9=JW|last10=Ménard |first10=C |last11=Camphausen |first11=K |last12=Coleman |first12=C. N. |last13=Sullivan |first13=F |last14=Steinberg |first14=S. M. |last15=Schlom |first15=J |last16=Dahut |first16=W |display-authors=8 }}
14. ^{{cite journal |doi=10.1002/pros.10130 |title=Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer |year=2002 |last1=Gulley |first1=James |last2=Chen |first2=Alice P. |last3=Dahut |first3=William |last4=Arlen |first4=Philip M. |last5=Bastian |first5=Anne |last6=Steinberg |first6=Seth M. |last7=Tsang |first7=Kwong |last8=Panicali |first8=Dennis |last9=Poole |first9=Diane |last10=Schlom |first10=Jeffrey |last11=Michael Hamilton |first11=J. |journal=The Prostate |volume=53 |issue=2 |pages=109–17 |pmid=12242725|display-authors=8 }}
15. ^{{PubMedAuthorSearch|Gulley|JL}}
16. ^{{cite journal |doi=10.1158/1078-0432.CCR-10-1762 |title=Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy |year=2010 |last1=Stein |first1=W. D. |last2=Gulley |first2=J. L. |last3=Schlom |first3=J. |last4=Madan |first4=R. A. |last5=Dahut |first5=W. |last6=Figg |first6=W. D. |last7=Ning |first7=Y.-m. |last8=Arlen |first8=P. M. |last9=Price |first9=D. |last10=Bates |first10=S. E. |last11=Fojo |first11=T. |journal=Clinical Cancer Research |volume=17 |issue=4 |pages=907–17 |pmid=21106727|display-authors=8 }}
17. ^http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=51902
18. ^{{cite journal |doi=10.1158/1078-0432.CCR-10-2463 |title=Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma |year=2010 |last1=Sarnaik |first1=A. A. |last2=Yu |first2=B. |last3=Yu |first3=D. |last4=Morelli |first4=D. |last5=Hall |first5=M. |last6=Bogle |first6=D. |last7=Yan |first7=L. |last8=Targan |first8=S. |last9=Solomon |first9=J. |last10=Nichol |first10=G. |last11=Yellin |first11=M. |last12=Weber |first12=J. S. |journal=Clinical Cancer Research |volume=17 |issue=4 |pages=896–906 |pmid=21106722 |pmc=3041838|display-authors=8 }}
19. ^{{cite journal |doi=10.1053/j.seminoncol.2010.09.015 |title=Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy |year=2010 |last1=Hoos |first1=Axel |last2=Ibrahim |first2=Ramy |last3=Korman |first3=Alan |last4=Abdallah |first4=Kald |last5=Berman |first5=David |last6=Shahabi |first6=Vafa |last7=Chin |first7=Kevin |last8=Canetta |first8=Renzo |last9=Humphrey |first9=Rachel |journal=Seminars in Oncology |volume=37 |issue=5 |pages=533–46 |pmid=21074069 }}
20. ^http://www.cancer.gov/clinicaltrials/results/ipilimumab0610

External links

  • Staff page at the Center for Cancer Research
{{Tumors}}{{Authority control}}{{DEFAULTSORT:Gulley, James L.}}

4 : Cancer researchers|Living people|Loma Linda University alumni|Year of birth missing (living people)
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/12 4:10:00